Phase II trial of weekly paclitaxel in patients with advanced melanoma

Melanoma Research

Volumn 15, Issue 5, 2005, Pages 453-459

  Walker, Leslie ^a   Schalch, Heidi ^a   King, David M ^a   Dietrich, Leah ^b   Eastman, Michael ^a   Kwak, Minjung ^c   Kim, KyungMann ^c   Albertini, Mark R ^a,d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b North Memorial Humphrey Cancer Center   (United States)

^c GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^d University of Wisconsin Health   (United States)

Author keywords

Chemotherapy; Human melanoma; Paclitaxel; Refractory melanoma

Indexed keywords

ANTIEMETIC AGENT; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RANITIDINE;

ADULT; AGED; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSION; HYPOTENSION; LUNG EMBOLISM; LUNG TOXICITY; LYMPHOCYTOPENIA; MELANOMA; METASTASIS; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PACLITAXEL; SURVIVAL RATE;

EID: 27644453414     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200510000-00015     Document Type: Article

References (19)

1. DeVita VT, Hellman S, Rosenberg SA. Cancer: Principles and Practice of Oncology, 6th edition. New York: Lippincott Williams & Wilkins; 2001, pp. 1973-1996.
2. Bogenrieder T, Elder DE, Herlyn M. Molecular and cellular biology. In: Balch CM, Houghton AN, Sober AJ, Soong S-J (editors): Cutaneous Melanoma. St. Louis, MO: Quality Medical Publishing; 2003, pp. 713-751.
3. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351:998-1012.
4. Wood AJ, Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995; 332:1004-1014.
5. Wiernick PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP. Phase I trial of Taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987; 5:1232-1239.
6. Legha SS, Ring S, Papadopoulos N, Raber M, Benjamin RS. A phase II trial of Taxol in metastatic melanoma. Cancer 1990; 65:2478-2481.
7. Einzig AI, Hochster H, Wiernik PH, Trump DL, Dutcher JP, Garowski F, et al. A phase II study of Taxol in patients with malignant melanoma. Invest New Drugs 1991; 9:59-64.
8. Lopes NM, Adams EG, Pitts TW, Bhuyan BK. Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 1993; 32:235-242.
9. Seidman AD, Hochhauser D, Gollub M, Edelman B, Yao TJ, Hudis CA, et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996; 14:1877-1884.
10. Akerley W, Glantz M, Choy H, Glantz L, Cortez S, Akerley W 3rd, et al. Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 1998; 16:153-158.
11. Ackerly W, Choy H, Glantz M, Safran H, Sikov W, Rege V, et al. Phase II trial of weekly paclitaxel for advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 1997; 16:Abstract 1616.
12. Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Currie V, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16:3353-3361.
13. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993; 85:388-393.
14. Hainsworth J, Thompson D, Greco FA. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small cell lung cancer. J Clin Oncol 1995; 7:1609-1614.
15. Millward MJ, Bishop JF, Friedlander M, Levi JA, Goldstein D, Olver IN, et al. Phase II trial of 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 1996; 14:142-148.
16. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, et al. Phase II trial of Taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 1993; 85:384-387.
17. Zonder JA, LoRusso P, Heilbrun L, Flaherty LE. Phase II trial of weekly paclitaxel as 2nd line treatment of metastatic melanoma. Proc Am Soc Clin Oncol 2000; 19:Abstract 2249.
18. Bedikian AY, Plager C, Papadopoulos N, Eton O, Ellerhorst J, Smith T. Phase II evaluation of paclitaxel by short iv infusion in metastatic melanoma. Melanoma Res 2004; 14:63-67.
19. Balch CM, Buzaid AC, Soong S, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.